top of page

Screenshot 2021-11-03 at 19.24_edited.png

BENEFICIARIES

OLIGOMED comprises 12 beneficiaries: 9 world-class academic units, 1 leading hospital unit, 1 high-quality SMEs, and 1 world-leading pharmaceutical company.

Find below the links to the individual beneficiaries.

University of Southampton, UK

University of Southampton, UK

Prof Eugen Stulz, School of Chemistry

CNRS Marseille

CNRS Marseille, FR

Dr Ling Peng, CINAM (UMR 7325)

Karolinska Institutet, SE

Karolinska Institutet, SE

Prof Roger Strömberg, Department of Biosciences and Nutrition.

Polish Academy of Sciences, PL

Polish Academy of Sciences, PL

Prof Dorota Gryko, Institute of Organic Chemistry

Stockholms Läns Landsting, SE

Stockholms Läns Landsting, SE

Prof Edvard Smith, Clinical Research Center at Karolinska University Hospital

Université de Bordeaux, FR

Université de Bordeaux, FR

Prof Philippe Barthélémy, INSERM U1212 / UMR CNRS 5320

Universiteit Gent, BE

Universiteit Gent, BE

Prof Annemieke Madder, Organic and Biomimetic Chemistry Research Group

AstraZeneca, SE

Dr Shalini Andersson, Cardiovascular, Renal and Metabolic Diseases (CVRM)

Università degli Studi di Udine, IT

Università degli Studi di Udine, IT

Dr Carlo Vascotto, School of Medicine

University of Cambridge, UK

University of Cambridge, UK

Prof Florian Hollfelder, School of Biology

Research Institutes of Sweden (RISE), SE

Research Institutes of Sweden (RISE), SE

Dr Ulf Tedebark, Surface, Process and Formulation

Sixfold Bioscience, UK

Sixfold Bioscience, UK

Dr Anna Perdrix Rosell, Managing Director, R&D

Back to Partners and Beneficiaries

bottom of page